GLP-2 TZ (also written GLP-2TZ or GLP 2 TZ) is a synthetic research peptide studied as a dual agonist: one molecule that activates both of the body’s main incretin receptors, the GLP-1 receptor and the GIP receptor. Earlier incretin compounds targeted the GLP-1 receptor alone. Combining both receptors in a single peptide made GLP-2 TZ one of the most closely studied metabolic compounds of the past decade. This overview covers its structure, how it acts at each receptor, what the published research has measured, and its regulatory status.
GLP-2 TZ is sold for laboratory research use only. This page summarizes published research and is not guidance for human or veterinary use.
At a glance
- Class: Synthetic peptide; dual agonist at the GIP and GLP-1 receptors
- Origin: Developed by a pharmaceutical research group; discovery and first clinical data published in 2018 (Coskun et al., 2018)
- Structure: 39-amino-acid peptide with a fatty-acid side chain that binds albumin and extends its half-life; about 4.8 kDa
- Main research areas: Receptor pharmacology and signaling bias, glycemic control, body weight
- Regulatory status: Research chemical, not for human use
Structure and origin
GLP-2 TZ is a fatty-acid-modified peptide designed for once-weekly administration in clinical studies. The fatty-acid chain lets it bind albumin in the blood, which slows clearance. The discovery paper characterized it in cell lines expressing the incretin receptors and in mice, then reported phase 1 studies in healthy volunteers and people with type 2 diabetes, concluding that its pharmacokinetics supported once-weekly administration (Coskun et al., 2018).
Mechanism: what the research shows
The two receptors GLP-2 TZ targets are the two main incretin receptors:
- GIP receptor: studied for glucose-dependent insulin release and effects on fat tissue and appetite.
- GLP-1 receptor: studied for insulin release, slowed gastric emptying and reduced food intake.
Later pharmacology work found that the molecule does not act on the two receptors equally. It binds the GIP receptor more strongly than the GLP-1 receptor, which the authors called an “imbalanced” mechanism. At the GIP receptor it behaves much like native GIP. At the GLP-1 receptor it shows signaling bias, favoring cAMP generation over β-arrestin recruitment, with weaker receptor internalization than native GLP-1 (Willard et al., 2020). That bias is one proposed explanation for how its effects differ from GLP-1-only compounds.
Key areas of study
Discovery and early clinical pharmacology
In mice, GLP-2 TZ activated both receptor pathways and improved glucose tolerance through both. Early human studies reported effects on glucose and body weight, with gastrointestinal events as the most common adverse events (Coskun et al., 2018).
Phase 2 in type 2 diabetes
A phase 2 trial compared GLP-2 TZ with placebo and with an approved GLP-1 receptor agonist in adults with type 2 diabetes, measuring HbA1c and body weight over 26 weeks (Frias et al., 2018).
Head-to-head glycemic trial
A 40-week phase 3 trial in 1,879 adults with type 2 diabetes compared GLP-2 TZ with a once-weekly GLP-1 receptor agonist. It reported larger reductions in HbA1c and body weight with GLP-2 TZ at all dose levels studied (Frías et al., 2021).
Body weight
A 72-week phase 3 trial enrolled 2,539 adults with obesity or overweight without diabetes. Mean weight change ranged from -15.0% in the lowest dose group to -20.9% in the highest, compared with -3.1% with placebo (Jastreboff et al., 2022).
What the evidence does not show
- All published human data come from clinical trials of a pharmaceutical-grade product. They say nothing about research-grade material.
- How much of the effect in humans comes from the GIP receptor versus the GLP-1 receptor is still debated.
- Signaling bias was measured in cell systems; its full meaning in whole organisms is still being studied.
Regulatory status
GLP-2 TZ from Rogue Compounds is a research chemical, not for human use. It is sold for laboratory research only and is not for human or veterinary use.
Handling and storage in the lab
Keep the lyophilized peptide sealed and refrigerated at 2–8 °C (36–46 °F), protected from light.
Sourcing and documentation
GLP-2 TZ is made in small batches for Rogue Compounds. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch, and the same COA is posted on the product page and in the COA Library. Our guide on how to read a peptide COA explains what to check.
Comparing GLP-2 TZ and GLP-3 RT? See GLP-3 RT vs GLP-2 TZ for a side-by-side comparison, or the GLP-3 RT research overview.
View GLP-2 TZ on Rogue Compounds
Frequently asked questions
What is GLP-2 TZ?
GLP-2 TZ is a synthetic research peptide studied as a dual agonist at the GIP and GLP-1 receptors. It is sold for laboratory research use only.
How is GLP-2 TZ different from GLP-3 RT?
GLP-2 TZ acts at two receptors, GIP and GLP-1. GLP-3 RT acts at those two plus the glucagon receptor.
Why is GLP-2 TZ called imbalanced?
Pharmacology studies found it binds the GIP receptor more strongly than the GLP-1 receptor, and that at the GLP-1 receptor it favors cAMP signaling over β-arrestin recruitment.
Is GLP-2 TZ for human use?
No. GLP-2 TZ is a research chemical, not for human use. It is sold for laboratory research only.
How should GLP-2 TZ be stored?
Store the lyophilized peptide sealed, refrigerated at 2–8 °C and protected from light.
References
- Coskun T, et al. Mol Metab. 2018;18:3-14. PMID 30473097
- Frias JP, et al. Lancet. 2018;392:2180-2193. PMID 30293770
- Willard FS, et al. JCI Insight. 2020;5(17):e140532. PMID 32730231
- Frías JP, et al. N Engl J Med. 2021;385:503-515. PMID 34170647
- Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. PMID 35658024
Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.